Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00311740 |
The purpose of this study is to compare the effect of the fixed combination of valsartan+hydrochlorothiazide (HCTZ) on blood pressure reduction with valsartan and HCTZ alone and whether the combination treatments are safe and well tolerated. The study aims to establish a dose response relationship for both monotherapies and the combinations. This study is being conducted in Japan.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Valsartan Drug: Hydrochlorothiazide |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Factorial Assignment, Safety/Efficacy Study |
Official Title: | A Multi-Center, Factorial Study to Evaluate Efficacy & Safety of 8 Wks Treatment With VAH631 [Valsartan (40
|
Estimated Enrollment: | 558 |
Study Start Date: | March 2006 |
Estimated Study Completion Date: | January 2007 |
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CVAH631B1303 |
Study First Received: | April 4, 2006 |
Last Updated: | February 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00311740 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Hypertension, Valsartan, Hydrochlorothiazide |
Essential Hypertension Sodium Chloride Symporter Inhibitors Diuretics Vascular Diseases Cardiovascular Agents |
Antihypertensive Agents Hydrochlorothiazide Valsartan Hypertension |
Molecular Mechanisms of Pharmacological Action Diuretics Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Vascular Diseases Cardiovascular Agents Antihypertensive Agents Hydrochlorothiazide |
Pharmacologic Actions Membrane Transport Modulators Natriuretic Agents Therapeutic Uses Cardiovascular Diseases Valsartan Hypertension |